Related Experiment Videos
CD44v6 is not relevant in colorectal tumour progression
1Colorectal Research Unit, Limerick Regional Hospital and University of Limerick, Ireland. mmorrin@mwhb.ie
International Journal of Colorectal Disease
|May 23, 2002
Summary
CD44v6 protein and variant mRNA expression do not correlate with colorectal cancer progression or patient survival. These findings suggest CD44v6 is not a pivotal factor in colorectal cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- The role of CD44 variants in colorectal cancer (CRC) prognosis is debated, with conflicting reports on their expression and clinical significance.
- Previous studies have yielded inconsistent results regarding the association between CD44 variants and patient outcomes in CRC.
Purpose of the Study:
- To investigate the expression of CD44v6 protein and CD44 variant mRNA in colorectal tumors.
- To determine the prognostic significance of CD44v6 protein and CD44 variant mRNA expression in colorectal cancer patients.
Main Methods:
- Immunohistochemistry was employed to detect CD44v6 protein expression in colorectal tumor specimens.
- Reverse transcriptase-polymerase chain reaction (RT-PCR) coupled with Southern blotting was used to analyze CD44 variant mRNA expression in tumor and normal tissues.
Main Results:
- CD44v6 protein expression levels were consistent across different Dukes' stages (50-67%), showing no correlation with disease progression or survival.
- CD44 variant mRNA was detected in 85% of tumors and 75% of normal tissues, with a majority of tumors expressing multiple variants.
- No association was found between CD44 variant mRNA expression, Dukes' stage, tumor differentiation, or survival rates.
Conclusions:
- CD44v6 protein does not appear to play a critical role in the progression of colorectal cancer.
- The expression patterns of CD44 variant transcripts suggest that individual variant expression is unlikely to predict in vivo outcomes in colorectal cancer.